Published in Hematol Oncol Clin North Am on April 13, 2013
Cerebral Hemorrhage Complicating Heparin-induced Thrombocytopenia after Percutaneous Coronary Intervention: A Clinical Dilemma of Medical Treatment. Chin Med J (Engl) (2015) 0.75
Is the incidence trend of heparin-induced thrombocytopenia decreased by the increased use of low-molecular-weight-heparin? Mediterr J Hematol Infect Dis (2015) 0.75
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med (1995) 6.86
Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol (2003) 4.86
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68
Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost (2006) 3.56
Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med (2006) 3.11
Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med (2001) 2.89
Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood (2000) 2.78
Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 2.56
Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost (1992) 2.31
Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med (2002) 2.23
Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood (2005) 2.08
Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost (2004) 2.04
A 14-year study of heparin-induced thrombocytopenia. Am J Med (1996) 2.03
What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol (2007) 1.96
Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost (2007) 1.85
How I treat heparin-induced thrombocytopenia. Blood (2012) 1.85
Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med (2000) 1.80
Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost (2004) 1.79
Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol (1995) 1.76
Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost (2008) 1.75
An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med (2003) 1.70
Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost (2009) 1.70
Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. Am J Med (2003) 1.64
Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation (2001) 1.64
Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes. J Lab Clin Med (1996) 1.58
Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med (2007) 1.57
Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost (2008) 1.56
Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood (2010) 1.55
Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg (2003) 1.55
Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg (2007) 1.54
Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost (2011) 1.54
Clinical and biologic features of patients suspected or confirmed to have heparin-induced thrombocytopenia in a cardiothoracic surgical ICU. Chest (2012) 1.52
Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest (2005) 1.49
Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels. Am J Med (2011) 1.48
PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI. Blood (2012) 1.48
Thrombocytopenia in a surgical ICU. Chest (1999) 1.45
Heparin-induced thrombocytopenia: laboratory studies. Blood (1988) 1.45
Heparin/PF4 antibodies formation after heparin treatment: temporal aspects and long-term follow-up. Am Heart J (2009) 1.45
Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia. Pharmacogenetics (2003) 1.45
Arterial embolism occurring during systemic heparin therapy. AMA Arch Surg (1958) 1.44
Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood (2005) 1.43
Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost (2005) 1.40
Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med (2005) 1.38
Studies of the immune response in heparin-induced thrombocytopenia. Blood (2009) 1.37
The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost (2010) 1.36
Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. Blood (2001) 1.36
The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol (2003) 1.33
Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost (2007) 1.31
Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med (2001) 1.30
Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation (1997) 1.28
The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy (2000) 1.26
Determinants of PF4/heparin immunogenicity. Blood (2007) 1.25
Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med (2003) 1.14
The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood (2005) 1.13
Platelet factor 4: production, structure, and physiologic and immunologic action. Proc Soc Exp Biol Med (1991) 1.11
How I diagnose and manage HIT. Hematology Am Soc Hematol Educ Program (2011) 1.11
Thrombocytopenia in the intensive care unit. Chest (1993) 1.11
Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion. Blood (2008) 1.09
Heparin-induced skin lesions. Lancet (2012) 1.05
Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med (1999) 1.05
Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood (2010) 1.04
Heparin-induced immune thrombocytopenia. N Engl J Med (1976) 1.04
Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol (1997) 1.04
Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood (2006) 1.02
High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol (1998) 1.01
The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care (2010) 1.00
Timely diagnosis and management of heparin-induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4T's score and particle gel immunoassay. Br J Haematol (2008) 1.00
Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood (2002) 0.97
The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. Br J Haematol (2002) 0.96
A clinical-laboratory approach contributing to a rapid and reliable diagnosis of heparin-induced thrombocytopenia. Thromb Res (2008) 0.95
Heparin induced thrombocytopenia: eight cases with thrombotic-hemorrhagic complications. Ann Surg (1977) 0.94
Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: a survey of North American specialized coagulation laboratories. Thromb Haemost (2007) 0.92
Heparin-induced thrombocytopaenia complicated by bilateral adrenal haemorrhage. Intensive Care Med (1991) 0.89
Heparin-induced thrombocytopenia (HIT) in 2011: an epidemic of overdiagnosis. Thromb Haemost (2011) 0.88
Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol (1993) 0.88
Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience. Clin Appl Thromb Hemost (2009) 0.87
Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients. Drugs Aging (2007) 0.86
Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin. Am J Hematol (1996) 0.85
Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia. J Thromb Haemost (2010) 0.85
Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism. Am J Med (2009) 0.84
Effectiveness of a new immunoassay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies. Thromb Haemost (2009) 0.83
Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass. J Thromb Haemost (2007) 0.83
Laboratory tests for heparin-induced thrombocytopenia: a multicenter study. Semin Hematol (1999) 0.83
Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia. Pharmacotherapy (2008) 0.83
Heparin-associated thrombocytopenia: a critical review and pooled analysis. Am J Med Sci (1993) 0.83
Improving the specificity of the PF4 ELISA in diagnosing heparin-induced thrombocytopenia. Am J Hematol (2012) 0.83
Heparin induced thrombocytopenia and thrombosis in a tertiary care hospital. Thromb Res (2009) 0.82
Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia. Drug Saf (2009) 0.82
Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia. J Thromb Haemost (2009) 0.82
Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparin-induced thrombocytopenia. Thromb Haemost (2010) 0.82
Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series. Anesth Analg (2003) 0.81
Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay. Thromb Res (2011) 0.81
Polymorphisms of protein tyrosine phosphatase CD148 influence FcγRIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia. Blood (2012) 0.81
Neurologic complications in immune-mediated heparin-induced thrombocytopenia. Neurology (2000) 0.81
Dynamic antibody-binding properties in the pathogenesis of HIT. Blood (2012) 1.59
Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood (2005) 1.59
Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood (2010) 1.55
Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah's Witness. Am J Hematol (2007) 1.54
PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI. Blood (2012) 1.48
Determinants of PF4/heparin immunogenicity. Blood (2007) 1.25
High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass. Blood (2013) 1.16
Heparin modifies the immunogenicity of positively charged proteins. Blood (2010) 1.00
Heparin-induced thrombocytopenia. Hematology Am Soc Hematol Educ Program (2013) 0.91
Novel diagnostic assays for heparin-induced thrombocytopenia. Blood (2013) 0.89
Platelet factor 4-heparin complexes trigger immune responses independently of the MyD88 pathway. Br J Haematol (2008) 0.82
Anticoagulation techniques in apheresis: from heparin to citrate and beyond. J Clin Apher (2012) 0.80
Influence of sample collection and storage on the detection of platelet factor 4-heparin antibodies. Am J Clin Pathol (2007) 0.80
Platelet factor 4/heparin antibodies in blood bank donors. Am J Clin Pathol (2010) 0.79
Distinct specificity and single-molecule kinetics characterize the interaction of pathogenic and non-pathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4. J Biol Chem (2013) 0.76
Transplantation-mediated alloimmune thrombocytopenia: Guidelines for utilization of thrombocytopenic donors. Liver Transpl (2008) 0.76
Lenalidomide-Associated ITP. Case Rep Hematol (2011) 0.75
Aprotinin improves functional outcome but not cerebral infarct size in an experimental model of stroke during cardiopulmonary bypass. Anesth Analg (2010) 0.75
Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia. J Clin Invest (2017) 0.75
American Society for Apheresis white paper: considerations for medical staff apheresis medicine physician credentialing and privileging. J Clin Apher (2012) 0.75